[go: up one dir, main page]

AR031101A1 - Compuestos de n-(2-hidroxi-3-aminosulfonil-fenil)-n'-fenil guanidina, composiciones farmaceuticasque los comprenden, y uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades que cursan con mediacion de quimioquinas. - Google Patents

Compuestos de n-(2-hidroxi-3-aminosulfonil-fenil)-n'-fenil guanidina, composiciones farmaceuticasque los comprenden, y uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades que cursan con mediacion de quimioquinas.

Info

Publication number
AR031101A1
AR031101A1 ARP010101346A ARP010101346A AR031101A1 AR 031101 A1 AR031101 A1 AR 031101A1 AR P010101346 A ARP010101346 A AR P010101346A AR P010101346 A ARP010101346 A AR P010101346A AR 031101 A1 AR031101 A1 AR 031101A1
Authority
AR
Argentina
Prior art keywords
alkyl
cr8r8
alkenyl
heterocyclic
aryl
Prior art date
Application number
ARP010101346A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR031101A1 publication Critical patent/AR031101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/64—X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Compuestos de N-(2-hidroxi-3-aminosulfonil-fenil)-N'-fenil guanidina utiles en el tratamiento de enfermedades que cursan con mediacion de la quimioquina Interleuquina-8 (IL-8). Tales compuestos están representados por la formula (1): R se selecciona entre el grupo que consta de ciano, OR11, C(O)NR15R16, R18, C(O)OR11, C(O)R11 y S(O)2R17; R'R'' se selecciona independientemente entre el grupo que consta de hidrogeno, NR6R7, OH, ORa, alquilo de C1-5, arilo, aril-alquilo de C1-4, aril-alquenilo de C2-4, cicloalquilo, cicloalquil-alquilo de C1-5, heteroarilo, heteroaril-alquilo de C1-4, heteroaril-alquenilo de C2-4, heterocíclico, heterocíclico-alquilo de C1-4 y un resto heterocíclico-alquenilo de C2-4, todos cuyos restos pueden estas sustituidos opcionalmente una a tres veces, independientemente, con un sustituyente seleccionado entre el grupo que consta de halogeno, nitro, alquilo de C1-4, halosustituido, alquilo de C1-4, amino, amina sustituida con mono- o diûalquilo de C1-4, ORa, C(O)Ra, NRaC(O)ORa, OC(O)NR6R7, hidroxi, NR9C(O)Ra, S(O)m'Ra, C(O)NR6R7, C(O)OH, C(O)ORa, S(O)tNR6R7 y NHS(O)tRa; o los dos sustituyentes Rb unidos forman un anillo de 3-10 miembros opcionalmente sustituido, y que contiene, además de alquilo de C1-4 opcionalmente sustituido, independientemente, 1 a 3 restos NRa, O, S, SO o SO2, cuyos restos pueden estar opcionalmente sustituidos; R''' se selecciona entre el grupo que consta de Y hidrogeno, halogeno, nitro, ciano, alquilo de C1-10 halosustituido, alquilo de C1-10, alquenilo de C2-10, alcoxi de C1-10, alcoxi de C1-10 halosustituido, azida, (CR8R8)qS(O)tRa, (CR8R8)qORa, hidroxi, alquilo de C1-4 sustituido con hidroxi, arilo, aril-alquilo de C1-4, ariloxi, aril-alquilo de C1-4oxi, aril-alquenilo de C2-10, heteroarilo, heteroarilalquilo, heteroaril-alquilo de C1-4oxi, heteroarilalquenilo de C2-10, heterocíclico, heterocíclico-alquilo de C1-4, heterocíclico-alquenilo de C2-10, (CR8R8)qNR4R5, alquenilo de C2-10C(O)NR4R5, (CR8R8)qC(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3R8, (CR8R8)qC(O)R11, alquenilo de C2-10C(O)R11, (CR8R8)qC(O)OR11, alquenilo de C2-10C(O)OR11, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (R8R8)qNHS(O)tR13, (CR8R8)qS(O)tNR4R5, (CR8R8)qC(NR4)NR4R5, y (CR8R8)qNR4C(NR5)R11; o dos restos Y juntos forman O-(CH2)s-O o un anillo de 5 a 6 miembros, saturado o insaturado, tal que los grupos alquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterocíclico y heterocíclicoalquilo pueden estar opcionalmente sustituidos; R1 se selecciona independientemente entre el grupo que consta de hidrogeno, halogeno, nitro, ciano, alquilo de C1-10, alquilo de C1-10 halosustituido, alquenilo de C2-10, alcoxi de C1-10, alcoxi de C1-10 halosustituido, azida, S(O)rR4, (CR8R8)qS(O)tR4, hidroxi, alquilo de C1-4 sustituido con hidroxi, arilo, aril-alquilo de C1-4, aril-alquenilo de C2-10, ariloxi, aril-alquilo de C1-4oxi, heteroarilo, heteroarilalquilo, heteroaril-alquenilo de C2-10, heteroaril-alquilo de C1-4oxi, heterocíclico, heterocíclico-alquilo de C1-4, heterocíclico-alquilo de C1-4oxi, heterocíclico-alquenilo de C2-10, (CR8R8)qNR4R5, (CR8R8)qC(O)NR4R5, alquenilo de C2-10C(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3R8, (CR8R8)qC(O)R11, alquenilo de C2-10C(O)R11, alquenilo de C2-10C(O)OR11, (CR8R8)qC(O)OR11, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)qC((NR4)NR4R5, (CR8R8)qNR4C(NR5)R11, (CR8R8)qNHS(O)tR13, y (CR8R8)qS(O)tNR4R5, o dos restos R1 juntos forman O(CH2)sO o un anillo arilo de 5 a 6 miembros, saturado o insaturado, en el que los restos alquilo, arilo, arilalquilo, heteroarilo y heterocíclico pueden estar opcionalmente sustituidos. Además se dan a conocer composiciones farmacéuticas que los comprenden y el uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades mediadas por quimioquinas
ARP010101346A 2000-03-24 2001-03-22 Compuestos de n-(2-hidroxi-3-aminosulfonil-fenil)-n'-fenil guanidina, composiciones farmaceuticasque los comprenden, y uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades que cursan con mediacion de quimioquinas. AR031101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19213200P 2000-03-24 2000-03-24

Publications (1)

Publication Number Publication Date
AR031101A1 true AR031101A1 (es) 2003-09-10

Family

ID=22708394

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101346A AR031101A1 (es) 2000-03-24 2001-03-22 Compuestos de n-(2-hidroxi-3-aminosulfonil-fenil)-n'-fenil guanidina, composiciones farmaceuticasque los comprenden, y uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades que cursan con mediacion de quimioquinas.

Country Status (31)

Country Link
US (1) US6680317B2 (es)
EP (1) EP1272175B1 (es)
JP (1) JP2004508287A (es)
KR (1) KR20040014901A (es)
CN (1) CN1452483A (es)
AP (1) AP1548A (es)
AR (1) AR031101A1 (es)
AT (1) ATE464893T1 (es)
AU (1) AU2001249354A1 (es)
BG (1) BG107035A (es)
BR (1) BR0108867A (es)
CA (1) CA2403787A1 (es)
CZ (1) CZ20023192A3 (es)
DE (1) DE60141896D1 (es)
DZ (1) DZ3333A1 (es)
EA (1) EA200201019A1 (es)
ES (1) ES2344587T3 (es)
HK (1) HK1053789A1 (es)
HU (1) HUP0302614A3 (es)
IL (1) IL151210A0 (es)
MA (1) MA25739A1 (es)
MX (1) MXPA02009355A (es)
MY (1) MY128154A (es)
NO (1) NO20024554D0 (es)
OA (1) OA12235A (es)
PE (1) PE20020839A1 (es)
PL (1) PL205103B1 (es)
SK (1) SK13682002A3 (es)
UY (1) UY26627A1 (es)
WO (1) WO2001072960A2 (es)
ZA (1) ZA200207576B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5170528A1 (es) * 1999-05-28 2002-06-27 Smithkline Beecham Corp Antagonistas de los receptores de la il-8 nistas del recpetor de la il-8
MY143477A (en) * 2002-10-29 2011-05-31 Smithkline Beecham Corp Il-8 receptor antagonists
AU2005245399A1 (en) 2004-05-12 2005-12-01 Schering Corporation CXCR1 and CXCR2 chemokine antagonists
JP2008517054A (ja) * 2004-10-20 2008-05-22 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
NZ572069A (en) * 2006-04-21 2011-09-30 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONIST N-[4-chloro-2-hydroxy-3-(3-piperidinylsulfonyl)-phenyl]-N'-(3-fluoro-2-methylphenyl)urea
BRPI0710559A2 (pt) * 2006-04-21 2011-08-16 Smithkline Beecham Corp antagonistas de receptores de il-8
PE20080943A1 (es) * 2006-06-23 2008-09-27 Smithkline Beecham Corp Sal toluenosulfonato de 4-{[6-cloro-3-({[(2-cloro-3-fluorofenil)amino]carbonil}amino)-2-hidroxifenil]sulfonil}-1-piperazinacarboxilato de 1,1-dimetiletilo como antagonista del receptor de il-8
US20090131329A1 (en) * 2007-09-14 2009-05-21 Edmund John Miller Treatment for allograft rejection
EP2611778B1 (en) * 2010-09-03 2015-08-05 Forma TM, LLC. Guanidine compounds and compositions for the inhibition of nampt
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
JP6138771B2 (ja) * 2012-05-08 2017-05-31 石原産業株式会社 置換安息香酸化合物の製造方法
CA3128946A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
EA003924B1 (ru) * 1998-09-23 2003-10-30 Туларик, Инк. Арилсульфонанилидмочевины
UY25842A1 (es) * 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8

Also Published As

Publication number Publication date
BR0108867A (pt) 2005-02-09
PL205103B1 (pl) 2010-03-31
US6680317B2 (en) 2004-01-20
SK13682002A3 (sk) 2003-06-03
IL151210A0 (en) 2003-04-10
HUP0302614A2 (hu) 2003-11-28
CA2403787A1 (en) 2001-10-04
NO20024554D0 (no) 2002-09-23
MXPA02009355A (es) 2003-02-12
KR20040014901A (ko) 2004-02-18
AP2002002599A0 (en) 2002-09-30
PL366315A1 (en) 2005-01-24
UY26627A1 (es) 2001-09-28
WO2001072960A3 (en) 2002-02-21
MA25739A1 (fr) 2003-04-01
ES2344587T3 (es) 2010-09-01
AP1548A (en) 2006-01-16
EA200201019A1 (ru) 2003-12-25
HK1053789A1 (zh) 2003-11-07
EP1272175A4 (en) 2005-08-31
CN1452483A (zh) 2003-10-29
EP1272175B1 (en) 2010-04-21
BG107035A (bg) 2003-04-30
EP1272175A2 (en) 2003-01-08
ZA200207576B (en) 2004-04-08
OA12235A (en) 2003-11-06
CZ20023192A3 (cs) 2003-02-12
JP2004508287A (ja) 2004-03-18
HUP0302614A3 (en) 2005-05-30
AU2001249354A1 (en) 2001-10-08
US20030216375A1 (en) 2003-11-20
PE20020839A1 (es) 2002-12-04
MY128154A (en) 2007-01-31
DE60141896D1 (de) 2010-06-02
ATE464893T1 (de) 2010-05-15
DZ3333A1 (fr) 2001-10-04
WO2001072960A2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
AR031101A1 (es) Compuestos de n-(2-hidroxi-3-aminosulfonil-fenil)-n'-fenil guanidina, composiciones farmaceuticasque los comprenden, y uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades que cursan con mediacion de quimioquinas.
AR032398A1 (es) Compuesto de escuaramida de sulfonamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dicha composicion
AR016134A1 (es) Compuestos derivados de propil-amida o butil-indanilo, composicion farmaceutica que los contiene y su uso para la fabricacion de un medicamento con metalo-proteinasas inhibidoras de la agrecanasa y matriz extracelular eficaz en el tratamiento de la artritis
AR033803A1 (es) Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
CO5261605A1 (es) Compustos farmaceuticos
CA2335477A1 (en) Sulfonamide inhibitors of aspartyl protease
UY26943A1 (es) Derivados de piridina
AR079648A1 (es) Inhibidores de la replicacion del virus de la hepatitis c
AR049662A1 (es) Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer
AR066012A1 (es) Derivados oxazolidinona, medicamento, composicion farmaceutica y uso en infecciones bacterianas
TR199901849T2 (xx) Arils�lfonilamino hidroksamik asit t�revleri.
AR015425A1 (es) Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
HUP0002092A2 (hu) Mátrix metalloproteináz inhibitor aktivitással rendelkező N-hidroxi-2-(alkil-,aril- vagy heteroaril-szulfanil-, szulfinil- vagy szulfonil)-3-szubsztituált alkil-, aril- vagy heteroarilamidok
ECSP034660A (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
CO4990929A1 (es) Compuestos de difenilurea sustituidos con sulfonamidas como antagonistas de los receptores de il-8
CA2505033A1 (en) Non-nucleoside reverse transcriptase inhibitors
AR048213A1 (es) 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol
ECSP024359A (es) Utilizacion de derivados de biguanida para fabricar un medicamento que tiene un efecto cicatrizante
AR050530A1 (es) Derivados de heteroaril sulfamida benzo-fusionada utiles como agentes anticonvulsivos
BRPI0407695A (pt) compostos, processo para a preparação de um composto, composições farmacêuticas que compreendem o composto, utilização dos compostos e processo de tratamento para diabetes do tipo 2
AR022889A1 (es) Agente desfoliante
UY28528A1 (es) Nuevos compuestos
CO2025002359A2 (es) Compuestos de pirazolopirimidina y su uso médico
AR023366A1 (es) Uso de benzolactamas n-carboximetil sustituidas para la fabricacion de un medicamento para la inhibicion de las metaloproteinasas de la matriz, paratratamiento de un estado de enfermedad neoplasico, para tratamiento de aterosclerosis, para tratamiento de una enfermedad inflamatoria cronica y paratra
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz

Legal Events

Date Code Title Description
FA Abandonment or withdrawal